Region: United States
Advanced Solid Tumors

OncoExTra® test

Don't miss half the genomic story. Personalize your advanced cancer care with ultra-comprehensive genomic profiling.

The full genomic story requires more than DNA alone

Interrogating both DNA and RNA in a single test, the OncoExTra test provides ultra-comprehensive genomic profiling that thoroughly detects clinically actionable mutations and fusions across each patient’s whole-exome (DNA) and whole-transcriptome* (RNA).1

Uncover more variants. Find more useful targets.

  • Ultra-comprehensive genomic profiling across nearly 20k genes in both tumor DNA + RNA, ensuring all possible genes are evaluated for genomic alterations upfront1
  • Broad and deep sequencing coverage accurately detects mutations, rare fusions, and transcript variants1
  • Patient-matched tumor-normal sequencing provides gold standard TMB calculation2 and allows for differentiation between germline and somatic variants
  • Optional immunohistochemical (IHC) panels and single stains provide an added level of detail†
Explore clinical utility

The OncoExTra test may be right for
your patient whose cancer is:

checkmark
Advanced or metastatic
checkmark
Unresponsive to treatment or recurrent
checkmark
Rare
checkmark
Aggressive
98%

of patients who receive
the OncoExTra® test
have $0 in out-of-
pocket costs3

99%

of patients have a
financial responsibility
of <$1003

The OncoExTra report:
putting a spotlight on what matters most

The easy-to-interpret report highlights the most actionable insights first for timely, shared decision-making:

  • Mutations and fusions associated with FDA-approved therapies deliver a comprehensive genomic picture‡
  • Immuno-oncology signatures (TMB/MSI) support personalized therapy selection
  • Clinical trial options to help inform next steps
Explore the report

Have a Provider Hub account?

Order the test
Set up a Provider Hub account

Fax your order

Download order form

* Whole-transcriptome with select variants reported in New York State
† IHC testing not currently available in New York State
‡The OncoExTra test was developed, and the performance characteristics validated by Genomic Health, Inc., a wholly-owned subsidiary of Exact Sciences Corporation following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. The OncoExTra test is performed at the Genomic Health Phoenix clinical laboratory. Exact Sciences clinical laboratories are accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing. This test has not been cleared or approved by the US Food and Drug Administration.
MSI, microsatellite instability; TMB, tumor mutational burden